Joint CDRH (Center for Devices and Radiological Health) and state quality-assurance surveys in nuclear medicine: Phase 2 - radiopharmaceuticals
The report discusses survey results on aspects of the quality assurance of radio-pharmaceuticals from 180 nuclear-medicine facilities in the United States. Data were collected from facilities in 8 states. Demographic information about nuclear-medicine operations and quality-assurance programs was gathered by state radiation-control-program personnel. The data collected from the survey show an incomplete acceptance of quality-assurance practices for radiopharmaceuticals. Most of the facilities in the survey indicated that, because an inferior radiopharmaceutical was prepared so infrequently, they did not believe it was cost-effective to perform extensive quality-assurance testing. The Center for Devices and Radiological Health hopes that the information from the survey will stimulate nuclear-medicine professionals and their organizations to encourage appropriate testing of all radiopharmaceuticals.
- Research Organization:
- Food and Drug Administration, Rockville, MD (USA). Center for Devices and Radiological Health
- OSTI ID:
- 7118185
- Report Number(s):
- PB-87-113031/XAB; HHS/PUB/FDA-86-8266; TRN: 87-007164
- Country of Publication:
- United States
- Language:
- English
Similar Records
Workshop manual for radionuclide handling and radiopharmaceutical quality assurance. Workshop manual report
Cost-effectiveness of routine radiochemical quality assurance testing of technetium Tc 99m radiopharmaceuticals
Related Subjects
NUCLEAR MEDICINE
RADIOPHARMACEUTICALS
QUALITY ASSURANCE
DATA ANALYSIS
SURVEYS
TECHNETIUM 99
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
DRUGS
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
NUCLEI
ODD-EVEN NUCLEI
RADIOISOTOPES
TECHNETIUM ISOTOPES
YEARS LIVING RADIOISOTOPES
560160* - Radionuclide Effects
Kinetics
& Toxicology